Edoxaban for stroke prevention in atrial fibrillation and factors associated with dosing : patient characteristics from the prospective observational ETNA-AF-China registry
© 2024. The Author(s)..
Real-world data on effectiveness and safety of a single non-vitamin K antagonist oral anticoagulant in the Chinese population with atrial fibrillation (AF) are limited. This study reports characteristics of patients treated with edoxaban and factors associated with dosing patterns from routine care in China. ETNA-AF-China (NCT04747496) is a multicentre, prospective, observational study enrolling edoxaban-treated patients from four economic regions with a targeted 2-year follow-up. Of the 4930 patients with AF (mean age: 70.2 ± 9.5 years; male, 57.1%), the mean creatinine clearance (CrCl), CHA2DS2-VASc, and HAS-BLED scores were 71.2 mL/min, 2.9, and 1.6. Overall, 6.4% of patients were perceived as frail by investigators. Available label dose reduction criteria (N = 4232) revealed that 3278 (77.5%) patients received recommended doses and 954 (22.5%) non-recommended doses. Northeast (53.0%) and West (43.1%) regions had the highest prescriptions of 60 mg and 30 mg recommended doses, respectively. Non-recommended 30 mg doses were more frequently prescribed in patients with antiplatelet use and history of heart failure than recommended 60 mg. Multivariate analysis identified advanced age as the strongest associated factor with non-recommended doses. Frailty had the strongest association with 30 mg except for age, and history of TIA was the most relevant factor associated with 60 mg. In conclusion, patients in the ETNA-AF-China study were predominantly aged 65 years and older, had mild-to-moderate renal impairment and good label adherence. Advanced age was associated with non-recommended doses, with frailty most common for non-recommended 30 mg and a history of TIA for the non-recommended 60 mg dose.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Scientific reports - 14(2024), 1 vom: 02. Feb., Seite 2778 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Guo, Xueyuan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticoagulants |
|---|
| Anmerkungen: |
Date Completed 12.02.2024 Date Revised 12.02.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41598-024-51776-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367973030 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367973030 | ||
| 003 | DE-627 | ||
| 005 | 20240212232109.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240203s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41598-024-51776-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1289.xml |
| 035 | |a (DE-627)NLM367973030 | ||
| 035 | |a (NLM)38307927 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Guo, Xueyuan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Edoxaban for stroke prevention in atrial fibrillation and factors associated with dosing |b patient characteristics from the prospective observational ETNA-AF-China registry |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.02.2024 | ||
| 500 | |a Date Revised 12.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Real-world data on effectiveness and safety of a single non-vitamin K antagonist oral anticoagulant in the Chinese population with atrial fibrillation (AF) are limited. This study reports characteristics of patients treated with edoxaban and factors associated with dosing patterns from routine care in China. ETNA-AF-China (NCT04747496) is a multicentre, prospective, observational study enrolling edoxaban-treated patients from four economic regions with a targeted 2-year follow-up. Of the 4930 patients with AF (mean age: 70.2 ± 9.5 years; male, 57.1%), the mean creatinine clearance (CrCl), CHA2DS2-VASc, and HAS-BLED scores were 71.2 mL/min, 2.9, and 1.6. Overall, 6.4% of patients were perceived as frail by investigators. Available label dose reduction criteria (N = 4232) revealed that 3278 (77.5%) patients received recommended doses and 954 (22.5%) non-recommended doses. Northeast (53.0%) and West (43.1%) regions had the highest prescriptions of 60 mg and 30 mg recommended doses, respectively. Non-recommended 30 mg doses were more frequently prescribed in patients with antiplatelet use and history of heart failure than recommended 60 mg. Multivariate analysis identified advanced age as the strongest associated factor with non-recommended doses. Frailty had the strongest association with 30 mg except for age, and history of TIA was the most relevant factor associated with 60 mg. In conclusion, patients in the ETNA-AF-China study were predominantly aged 65 years and older, had mild-to-moderate renal impairment and good label adherence. Advanced age was associated with non-recommended doses, with frailty most common for non-recommended 30 mg and a history of TIA for the non-recommended 60 mg dose | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a edoxaban |2 NLM | |
| 650 | 7 | |a NDU3J18APO |2 NLM | |
| 650 | 7 | |a Factor Xa Inhibitors |2 NLM | |
| 650 | 7 | |a Pyridines |2 NLM | |
| 650 | 7 | |a Thiazoles |2 NLM | |
| 700 | 1 | |a Du, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Mingxing |e verfasserin |4 aut | |
| 700 | 1 | |a Ou, Wenchao |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Xuebin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zhifang |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Zheng |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Guoqin |e verfasserin |4 aut | |
| 700 | 1 | |a Long, Mingzhi |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, Guotian |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Tong |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xiaoyan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Dongsheng |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Manhua |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Yugang |e verfasserin |4 aut | |
| 700 | 1 | |a Lai, Chunlin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xuelian |e verfasserin |4 aut | |
| 700 | 1 | |a Yi, Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Xiang, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Cathy |e verfasserin |4 aut | |
| 700 | 1 | |a Unverdorben, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Changsheng |e verfasserin |4 aut | |
| 700 | 0 | |a ETNA-AF-China Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, Yuehui |e investigator |4 oth | |
| 700 | 1 | |a Qi, Heng |e investigator |4 oth | |
| 700 | 1 | |a Jia, Zhisheng |e investigator |4 oth | |
| 700 | 1 | |a Ji, Xiaojun |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Yuqing |e investigator |4 oth | |
| 700 | 1 | |a Liang, Xue |e investigator |4 oth | |
| 700 | 1 | |a Deng, Bing |e investigator |4 oth | |
| 700 | 1 | |a Liu, Jieyun |e investigator |4 oth | |
| 700 | 1 | |a Ma, Juan |e investigator |4 oth | |
| 700 | 1 | |a Song, Cangsang |e investigator |4 oth | |
| 700 | 1 | |a Feng, Huifang |e investigator |4 oth | |
| 700 | 1 | |a Luo, Suxin |e investigator |4 oth | |
| 700 | 1 | |a Wang, Jingfeng |e investigator |4 oth | |
| 700 | 1 | |a Li, Lun |e investigator |4 oth | |
| 700 | 1 | |a Xiao, Yongqi |e investigator |4 oth | |
| 700 | 1 | |a Cui, Junyou |e investigator |4 oth | |
| 700 | 1 | |a Cheng, Xiang |e investigator |4 oth | |
| 700 | 1 | |a Huang, Zheng |e investigator |4 oth | |
| 700 | 1 | |a Wei, Jiafu |e investigator |4 oth | |
| 700 | 1 | |a Cheng, Jinfang |e investigator |4 oth | |
| 700 | 1 | |a Li, Haiyan |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Jun |e investigator |4 oth | |
| 700 | 1 | |a Jiang, Weihong |e investigator |4 oth | |
| 700 | 1 | |a Liu, Jie |e investigator |4 oth | |
| 700 | 1 | |a Min, Xinwen |e investigator |4 oth | |
| 700 | 1 | |a Gao, Peng |e investigator |4 oth | |
| 700 | 1 | |a Gao, Lianjun |e investigator |4 oth | |
| 700 | 1 | |a Huang, Zhouqing |e investigator |4 oth | |
| 700 | 1 | |a Wang, Ruxing |e investigator |4 oth | |
| 700 | 1 | |a Li, Ying |e investigator |4 oth | |
| 700 | 1 | |a Ye, Zebin |e investigator |4 oth | |
| 700 | 1 | |a Wang, Xubo |e investigator |4 oth | |
| 700 | 1 | |a Lai, Hengli |e investigator |4 oth | |
| 700 | 1 | |a Wang, Lihong |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Minli |e investigator |4 oth | |
| 700 | 1 | |a Wang, Changqian |e investigator |4 oth | |
| 700 | 1 | |a Mao, Wei |e investigator |4 oth | |
| 700 | 1 | |a Chen, Xiaohua |e investigator |4 oth | |
| 700 | 1 | |a Wang, Zhirong |e investigator |4 oth | |
| 700 | 1 | |a Liu, Fang |e investigator |4 oth | |
| 700 | 1 | |a Xie, Xiaolin |e investigator |4 oth | |
| 700 | 1 | |a Xu, Zhenggui |e investigator |4 oth | |
| 700 | 1 | |a Dong, Bin |e investigator |4 oth | |
| 700 | 1 | |a Zeng, Hesong |e investigator |4 oth | |
| 700 | 1 | |a Peng, Jianqiang |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Lihua |e investigator |4 oth | |
| 700 | 1 | |a Zhao, Qingyan |e investigator |4 oth | |
| 700 | 1 | |a Liu, Fucheng |e investigator |4 oth | |
| 700 | 1 | |a Guo, Caixia |e investigator |4 oth | |
| 700 | 1 | |a Tang, Lijiang |e investigator |4 oth | |
| 700 | 1 | |a Li, Xianjin |e investigator |4 oth | |
| 700 | 1 | |a Zhou, Jing |e investigator |4 oth | |
| 700 | 1 | |a Yang, Xinchun |e investigator |4 oth | |
| 700 | 1 | |a Chen, Xiaoshu |e investigator |4 oth | |
| 700 | 1 | |a Liu, Yajuan |e investigator |4 oth | |
| 700 | 1 | |a Tong, Tiebi |e investigator |4 oth | |
| 700 | 1 | |a Tang, Guanmin |e investigator |4 oth | |
| 700 | 1 | |a Liu, Jian |e investigator |4 oth | |
| 700 | 1 | |a Lin, Meise |e investigator |4 oth | |
| 700 | 1 | |a Liu, Bin |e investigator |4 oth | |
| 700 | 1 | |a Fu, Guosheng |e investigator |4 oth | |
| 700 | 1 | |a Wang, Weimin |e investigator |4 oth | |
| 700 | 1 | |a Yang, Qing |e investigator |4 oth | |
| 700 | 1 | |a Tang, Baopeng |e investigator |4 oth | |
| 700 | 1 | |a Ran, Boli |e investigator |4 oth | |
| 700 | 1 | |a Xu, Jianjiang |e investigator |4 oth | |
| 700 | 1 | |a Yin, Chunlin |e investigator |4 oth | |
| 700 | 1 | |a Yang, Pingzhen |e investigator |4 oth | |
| 700 | 1 | |a Yang, Fujie |e investigator |4 oth | |
| 700 | 1 | |a Bai, Ming |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Jian |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 14(2024), 1 vom: 02. Feb., Seite 2778 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g number:1 |g day:02 |g month:02 |g pages:2778 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41598-024-51776-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |e 1 |b 02 |c 02 |h 2778 | ||